Disposition in humans of racemic picenadol, an opioid analgesic

P. M. Franz, S. L. Anliker, John Callaghan, K. A. DeSante, P. H. Dhahir, R. L. Nelson, A. Rubin

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Racemic picenadol is being tested clinically as a analgesic. The (+)-enantiomer of picenadol is an opioid agonist and the (-)-enantiomer is a weak agonist/antagonist. The disposition of racemic [14C]picenadol was studied in healthy men after a single dose was administered im (N = 3) and orally (N = 5). After the dose, virtually none of the radioactivitiy that appeared in blood was associated with the red cells. In plasma, approximately 4% of the radioactivity was attributable to the parent drug, the remainder being picenadol glucuronide (~35%) and other metabolites. The t( 1/2 ) for total radioactivity was 6 hr, that for the unchanged drug was 3.5 hr. Picenadol was present in plasma almost exclusively as the (+)-enantiomer. However, after incubation with glucuronidase and sulfatase, plasma contained 2 to 4 times more (-)- than (+)-picenadol, indicating that more conjugated (-)-picenadol than conjugated (+)-picenadol was in the plasma. After im and oral administration of [14C]picenadol, plasma levels of radioactivity were generally 10 and 70 times higher than those in saliva, respectively. More than 90% of the administered radioactivity was excreted in the urine, mostly as picenadol glucuronide, and lesser amounts of picenadol sulfate and N-desmethylpicenadol sulfate. Only about 1% of the administered dose of picenadol appeared unchanged in urine. The disposition of racemic picenadol in humans was stereoselective, the (-)-picenadol apparently being metabolized preferentially over the (+)-enantiomer. This finding was of particular interest in view of the dissimilar pharmacologic activities of the enantiomers. In a separate multiple dose study of picenadol, the disposition of the drug was found to be similar to that in the single dose study.

Original languageEnglish (US)
Pages (from-to)968-973
Number of pages6
JournalDrug Metabolism and Disposition
Volume18
Issue number6
StatePublished - 1990

Fingerprint

picenadol
Opioid Analgesics
Enantiomers
Radioactivity
Plasmas
Glucuronides
Sulfates

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Franz, P. M., Anliker, S. L., Callaghan, J., DeSante, K. A., Dhahir, P. H., Nelson, R. L., & Rubin, A. (1990). Disposition in humans of racemic picenadol, an opioid analgesic. Drug Metabolism and Disposition, 18(6), 968-973.

Disposition in humans of racemic picenadol, an opioid analgesic. / Franz, P. M.; Anliker, S. L.; Callaghan, John; DeSante, K. A.; Dhahir, P. H.; Nelson, R. L.; Rubin, A.

In: Drug Metabolism and Disposition, Vol. 18, No. 6, 1990, p. 968-973.

Research output: Contribution to journalArticle

Franz, PM, Anliker, SL, Callaghan, J, DeSante, KA, Dhahir, PH, Nelson, RL & Rubin, A 1990, 'Disposition in humans of racemic picenadol, an opioid analgesic', Drug Metabolism and Disposition, vol. 18, no. 6, pp. 968-973.
Franz PM, Anliker SL, Callaghan J, DeSante KA, Dhahir PH, Nelson RL et al. Disposition in humans of racemic picenadol, an opioid analgesic. Drug Metabolism and Disposition. 1990;18(6):968-973.
Franz, P. M. ; Anliker, S. L. ; Callaghan, John ; DeSante, K. A. ; Dhahir, P. H. ; Nelson, R. L. ; Rubin, A. / Disposition in humans of racemic picenadol, an opioid analgesic. In: Drug Metabolism and Disposition. 1990 ; Vol. 18, No. 6. pp. 968-973.
@article{c74b212a24d6485cb381ae7121063d38,
title = "Disposition in humans of racemic picenadol, an opioid analgesic",
abstract = "Racemic picenadol is being tested clinically as a analgesic. The (+)-enantiomer of picenadol is an opioid agonist and the (-)-enantiomer is a weak agonist/antagonist. The disposition of racemic [14C]picenadol was studied in healthy men after a single dose was administered im (N = 3) and orally (N = 5). After the dose, virtually none of the radioactivitiy that appeared in blood was associated with the red cells. In plasma, approximately 4{\%} of the radioactivity was attributable to the parent drug, the remainder being picenadol glucuronide (~35{\%}) and other metabolites. The t( 1/2 ) for total radioactivity was 6 hr, that for the unchanged drug was 3.5 hr. Picenadol was present in plasma almost exclusively as the (+)-enantiomer. However, after incubation with glucuronidase and sulfatase, plasma contained 2 to 4 times more (-)- than (+)-picenadol, indicating that more conjugated (-)-picenadol than conjugated (+)-picenadol was in the plasma. After im and oral administration of [14C]picenadol, plasma levels of radioactivity were generally 10 and 70 times higher than those in saliva, respectively. More than 90{\%} of the administered radioactivity was excreted in the urine, mostly as picenadol glucuronide, and lesser amounts of picenadol sulfate and N-desmethylpicenadol sulfate. Only about 1{\%} of the administered dose of picenadol appeared unchanged in urine. The disposition of racemic picenadol in humans was stereoselective, the (-)-picenadol apparently being metabolized preferentially over the (+)-enantiomer. This finding was of particular interest in view of the dissimilar pharmacologic activities of the enantiomers. In a separate multiple dose study of picenadol, the disposition of the drug was found to be similar to that in the single dose study.",
author = "Franz, {P. M.} and Anliker, {S. L.} and John Callaghan and DeSante, {K. A.} and Dhahir, {P. H.} and Nelson, {R. L.} and A. Rubin",
year = "1990",
language = "English (US)",
volume = "18",
pages = "968--973",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "6",

}

TY - JOUR

T1 - Disposition in humans of racemic picenadol, an opioid analgesic

AU - Franz, P. M.

AU - Anliker, S. L.

AU - Callaghan, John

AU - DeSante, K. A.

AU - Dhahir, P. H.

AU - Nelson, R. L.

AU - Rubin, A.

PY - 1990

Y1 - 1990

N2 - Racemic picenadol is being tested clinically as a analgesic. The (+)-enantiomer of picenadol is an opioid agonist and the (-)-enantiomer is a weak agonist/antagonist. The disposition of racemic [14C]picenadol was studied in healthy men after a single dose was administered im (N = 3) and orally (N = 5). After the dose, virtually none of the radioactivitiy that appeared in blood was associated with the red cells. In plasma, approximately 4% of the radioactivity was attributable to the parent drug, the remainder being picenadol glucuronide (~35%) and other metabolites. The t( 1/2 ) for total radioactivity was 6 hr, that for the unchanged drug was 3.5 hr. Picenadol was present in plasma almost exclusively as the (+)-enantiomer. However, after incubation with glucuronidase and sulfatase, plasma contained 2 to 4 times more (-)- than (+)-picenadol, indicating that more conjugated (-)-picenadol than conjugated (+)-picenadol was in the plasma. After im and oral administration of [14C]picenadol, plasma levels of radioactivity were generally 10 and 70 times higher than those in saliva, respectively. More than 90% of the administered radioactivity was excreted in the urine, mostly as picenadol glucuronide, and lesser amounts of picenadol sulfate and N-desmethylpicenadol sulfate. Only about 1% of the administered dose of picenadol appeared unchanged in urine. The disposition of racemic picenadol in humans was stereoselective, the (-)-picenadol apparently being metabolized preferentially over the (+)-enantiomer. This finding was of particular interest in view of the dissimilar pharmacologic activities of the enantiomers. In a separate multiple dose study of picenadol, the disposition of the drug was found to be similar to that in the single dose study.

AB - Racemic picenadol is being tested clinically as a analgesic. The (+)-enantiomer of picenadol is an opioid agonist and the (-)-enantiomer is a weak agonist/antagonist. The disposition of racemic [14C]picenadol was studied in healthy men after a single dose was administered im (N = 3) and orally (N = 5). After the dose, virtually none of the radioactivitiy that appeared in blood was associated with the red cells. In plasma, approximately 4% of the radioactivity was attributable to the parent drug, the remainder being picenadol glucuronide (~35%) and other metabolites. The t( 1/2 ) for total radioactivity was 6 hr, that for the unchanged drug was 3.5 hr. Picenadol was present in plasma almost exclusively as the (+)-enantiomer. However, after incubation with glucuronidase and sulfatase, plasma contained 2 to 4 times more (-)- than (+)-picenadol, indicating that more conjugated (-)-picenadol than conjugated (+)-picenadol was in the plasma. After im and oral administration of [14C]picenadol, plasma levels of radioactivity were generally 10 and 70 times higher than those in saliva, respectively. More than 90% of the administered radioactivity was excreted in the urine, mostly as picenadol glucuronide, and lesser amounts of picenadol sulfate and N-desmethylpicenadol sulfate. Only about 1% of the administered dose of picenadol appeared unchanged in urine. The disposition of racemic picenadol in humans was stereoselective, the (-)-picenadol apparently being metabolized preferentially over the (+)-enantiomer. This finding was of particular interest in view of the dissimilar pharmacologic activities of the enantiomers. In a separate multiple dose study of picenadol, the disposition of the drug was found to be similar to that in the single dose study.

UR - http://www.scopus.com/inward/record.url?scp=0025670112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025670112&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 968

EP - 973

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 6

ER -